TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33400032

Group type: EXPERIMENTAL
Intervention: Structured MRI template report including 8 key descriptors of anal fistulas
Number of subjects: 0
Study: 33400164

Group type: EXPERIMENTAL
Intervention: Nursing home residents with COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General population with COVID-19
Number of subjects: 0
Study: 33400438

Group type: EXPERIMENTAL
Intervention: Contralateral oblique view (CLO) at 60 degrees
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral oblique view (CLO) at 40 degrees
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral oblique view (CLO) at 50 degrees
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral oblique view (CLO) at 90 degrees
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lateral view
Number of subjects: 30
Study: 33400439

Group type: EXPERIMENTAL
Intervention: Chiropractic care with visit frequency more than once per week for CLBP
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Chiropractic care with visit frequency (general)
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Chiropractic care (general)
Number of subjects: 2576
Study: 33400777

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents (DAA) treatment
Number of subjects: 50861
Study: 33400907

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33401131

Group type: EXPERIMENTAL
Intervention: Bending trunk test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sit to Stand test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sock test
Number of subjects: 0
Study: 33401364

Group type: EXPERIMENTAL
Intervention: Postoperative home monitoring system (remote patient monitoring, Telus Canada)
Number of subjects: 54
Study: 33401365

Group type: EXPERIMENTAL
Intervention: Postoperative home monitoring (POHM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Historical standard of care (control)
Number of subjects: 54
Study: 33401363

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Pathway (ERP) including patient education, psychological screening, multimodal pre-emptive analgesia, nausea prophylaxis, early Foley catheter removal, and respiratory exercises.
Number of subjects: 29
Study: 33401367

Group type: EXPERIMENTAL
Intervention: Recovery Assessment by Phone Points (RAPP) app with SwQoR questionnaire
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 494
Study: 33401942

Group type: EXPERIMENTAL
Intervention: General practitioners' understanding of HFpEF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Communication of diagnosis
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Management of people with HFpEF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuity of care
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Learning needs for GPs
Number of subjects: 35
Study: 33402222

Group type: EXPERIMENTAL
Intervention: Combination therapy of brown flaxseed (30 g milled) and hesperidin (two 500 mg capsules) during lifestyle intervention
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination therapy of brown flaxseed and hesperidin
Number of subjects: 48
Study: 33402367

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control youth with normal weight or obesity and youth with Type 2 Diabetes (T2D)
Number of subjects: 0
Study: 33402692

Group type: EXPERIMENTAL
Intervention: SSTR2 targeting using PEN-221, a cytotoxic drug conjugate.
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: SSTR2 expression in NPC patients.
Number of subjects: 402
Study: 33402861

Group type: EXPERIMENTAL
Intervention: WeReha device (12-week physiotherapy program including balance exercises, upper and lower limb exercises with specific motor tasks using a biofeedback system and exergaming)
Number of subjects: 25
Study: 33403007

Group type: EXPERIMENTAL
Intervention: nal-IRI 50 mg/m² with fluorouracil/leucovorin (5-FU/LV) and oxaliplatin, administered in three cycles before and three cycles after surgical resection
Number of subjects: 72
Study: 33403207

Group type: EXPERIMENTAL
Intervention: 12 weeks of 'standard care' exercises
Number of subjects: 23
Study: 33403364

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO) initiated within 30 minutes of collapse
Number of subjects: 6
Study: 33403367

Group type: EXPERIMENTAL
Intervention: NEWS2
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: CURB-65
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: PSI
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: SIRS
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: qSOFA
Number of subjects: 175
Study: 33403401

Group type: EXPERIMENTAL
Intervention: Drugs used to prevent CIPN (B vitamins, calcium and magnesium infusion)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Therapeutic adjustment of neurotoxic anticancer drugs
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pharmacological management of CIPN
Number of subjects: 210
Study: 33403831

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonist (MRA) added to conventional anti-failure therapy
Number of subjects: 12
Study: 33404200

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study: 33404367

Group type: EXPERIMENTAL
Intervention: Contraceptive methods used by patients with comorbidities; specific methods not detailed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on control group not available.
Number of subjects: 0
Study: 33404513

Group type: EXPERIMENTAL
Intervention: PACO app (web-based eHealth app) for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list condition (no intervention for 4 weeks)
Number of subjects: 60
Study: 33404519

Group type: EXPERIMENTAL
Intervention: 0.5 mg/day entecavir
Number of subjects: 29

Group type: COMPARATOR
Intervention: 1.0 mg/day entecavir
Number of subjects: 29
Study: 33404681

Group type: EXPERIMENTAL
Intervention: Lower MCRI (Metabolic Clearance Rate of Insulin)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: MCRI
Number of subjects: 570
Study: 33404789

Group type: EXPERIMENTAL
Intervention: White matter lesion (WML) burden
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of the DMN
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Additional networks
Number of subjects: 660
Study: 33405090

Group type: EXPERIMENTAL
Intervention: Selumetinib (KOSELUGO™; ARRY-142886)
Number of subjects: 0
Study: 33405269

Group type: EXPERIMENTAL
Intervention: gemcitabine, trastuzumab plus erlotinib
Number of subjects: 63
Study: 33405950

Group type: EXPERIMENTAL
Intervention: Negative EOI MRD levels
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Intermediate EOI MRD levels
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High EOI MRD levels
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High EOI MRD with AML-like consolidation therapy
Number of subjects: 249
Study: 33405951

Group type: EXPERIMENTAL
Intervention: Average-risk treatment group
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: High-risk treatment group
Number of subjects: 330

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 330
Study: 33406266

Group type: EXPERIMENTAL
Intervention: Nap sleep in healthy young adults
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nap sleep in healthy older adults
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nap sleep in older patients with mild cognitive impairment
Number of subjects: 3
Study: 33406276

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33406328

Group type: EXPERIMENTAL
Intervention: Sitagliptin (600 mg every 12 hours starting the day before transplantation until day 14 after transplantation) plus tacrolimus and sirolimus
Number of subjects: 36
Study: 33406989

Group type: EXPERIMENTAL
Intervention: Social marketing initiative to promote balance and strength classes
Number of subjects: 0
Study: 33406996

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2579
Study: 33407104

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications including individual counseling for nutritional education and physical activity over a 2-month weight reduction program.
Number of subjects: 36
Study: 33407184

Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI) identified based on changes in blood creatinine levels according to the Kidney Disease: Improving Global Outcomes criteria.
Number of subjects: 30194

Group type: EXPERIMENTAL
Intervention: Older adults aged 75 years or older.
Number of subjects: 30194

Group type: EXPERIMENTAL
Intervention: AKI risk in older adults.
Number of subjects: 30194

Group type: EXPERIMENTAL
Intervention: AKI association with in-hospital mortality.
Number of subjects: 30194
Study: 33407194

Group type: EXPERIMENTAL
Intervention: 6-month supervised multicomponent exercise intervention (aerobic, muscular resistance, flexibility and postural exercises)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 6-month supervised multicomponent exercise intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 64
Study: 33407214

Group type: EXPERIMENTAL
Intervention: Days from ovulation until onset of nausea or vomiting
Number of subjects: 256

Group type: COMPARATOR
Intervention: Days from last menstrual period (LMP) until onset of nausea or vomiting
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotrophin rise
Number of subjects: 256
Study: 33407224

Group type: EXPERIMENTAL
Intervention: ravulizumab
Number of subjects: 8
Study: 33407305

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Emotional coping
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Coping self-efficacy
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 740
Study: 33407440

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 148
Study: 33407577

Group type: EXPERIMENTAL
Intervention: vemurafenib + PEG-IFN-α-2b
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: vemurafenib + cobimetinib + PEG-IFN-α-2b
Number of subjects: 8
Study: 33407671

Group type: EXPERIMENTAL
Intervention: PDHS-specific leukocyte genes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PQDS-specific genes in leukocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hsa-miR-122-5p
Number of subjects: 0
Study: 33407676

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa enzyme replacement therapy (once-weekly intravenous infusions)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa enzyme replacement therapy
Number of subjects: 19
Study: 33407685

Group type: EXPERIMENTAL
Intervention: Fingolimod treatment for 12 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CSF BDNF levels
Number of subjects: 6
Study: 33407727

Group type: EXPERIMENTAL
Intervention: 3-month exergame intervention (simultaneous moderate-intensity aerobic cycling and cognitive training)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cycling only
Number of subjects: 96

Group type: COMPARATOR
Intervention: Attention control (stretching)
Number of subjects: 96
Study: 33407782

Group type: EXPERIMENTAL
Intervention: 12-week progressive exercise intervention consisting of supervised exercise sessions delivered three times per week by a trained exercise specialist.
Number of subjects: 0
Study: 33407794

Group type: EXPERIMENTAL
Intervention: 5 × 10^6 autologous adipose-derived stromal cells (ADSCs)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 × 10^6 autologous adipose-derived stromal cells (ADSCs)
Number of subjects: 9
Study: 33407910

Group type: EXPERIMENTAL
Intervention: iACT (app-assisted acceptance and commitment therapy)
Number of subjects: 12
Study: 33407923

Group type: EXPERIMENTAL
Intervention: In-bed cycling (20 minutes, 5 days/week)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: In-bed cycling
Number of subjects: 23
Study: 33407939

Group type: EXPERIMENTAL
Intervention: Precision Family Spirit
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Family Spirit
Number of subjects: 60
Study: 33407947

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (12-weekly sessions on education, physical activity, stress management, coping skills training) followed by 3 months of continued support and 6 months of skill maintenance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 80
Study: 33408185

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 0
Study: 33408198

Group type: EXPERIMENTAL
Intervention: Health status measured with the EuroQol-5-dimensions-3-levels (EQ-5D) and EuroQol Visual Analogue Scale at 1 week, 1, 3, 6, 12 and 24 months after injury.
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: Health status dimensions including mobility, pain/discomfort, and usual activities.
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: Pre-injury health status, frailty, and length of stay at the hospital.
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: Spine injury, lower and upper extremity injury.
Number of subjects: 4883

Group type: EXPERIMENTAL
Intervention: Traumatic brain injury.
Number of subjects: 4883
Study: 33408199

Group type: EXPERIMENTAL
Intervention: Multimodal pain assessment using sensor-fusion and machine-learning algorithms (facial electromyography, ECG, electrodermal activity, changes in oxygen saturations, skin perfusion, electroencephalography)
Number of subjects: 60
Study: 33408512

Group type: EXPERIMENTAL
Intervention: GMB 120 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: GMB 240 mg
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 33408684

Group type: EXPERIMENTAL
Intervention: Theta-Burst Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-Controlled
Number of subjects: 0
Study: 33408796

Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Medicine (SAM) combined with 1% diclofenac ultrasound gel patch
Number of subjects: 32
Study: 33408874

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise training (HIT-RT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HIT-RT
Number of subjects: 43
Study: 33409259

Group type: EXPERIMENTAL
Intervention: Enteroadsorbent Polymethylsiloxane Polyhydrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotic
Number of subjects: 0
Study: 33409402

Group type: EXPERIMENTAL
Intervention: Psychometric Hepatic Encephalopathy Score (PHES)
Number of subjects: 54
Study: 33409459

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 33409860

Group type: EXPERIMENTAL
Intervention: Change of ultrasonographic (US) air bronchogram score (USINCHILD score) after 48 hours
Number of subjects: 36
Study: 33409867

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 25 mL, Volume Cohort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 40 mL, Volume Cohort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 25 mL/h, Flow Rate Cohort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 75 mL/h, Flow Rate Cohort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20 at 100 mL/h, Flow Rate Cohort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20, Volume Cohort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20, Flow Rate Cohort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous IgPro20
Number of subjects: 33
Study: 33409898

Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg orally twice daily continuously until progression or unacceptable toxicity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 14
Study: 33410093

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30/70 (BIAsp 30) in an insulin pen (FlexPen)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30/70 (BIAsp 30)
Number of subjects: 505
Study: 33410109

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) and Indapamide combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indapamide alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0
Study: 33410356

Group type: EXPERIMENTAL
Intervention: Unilateral femoral lengthening
Number of subjects: 10
Study: 33410485

Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection
Number of subjects: 18120
Study: 33410523

Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) plus standard immunosuppressive therapy (IST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Historical IST cohort (n = 87)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) plus standard IST
Number of subjects: 40
Study: 33410760

Group type: EXPERIMENTAL
Intervention: mHealth DRIVE program
Number of subjects: 84

Group type: COMPARATOR
Intervention: SafeCare provider feedback
Number of subjects: 84
Study: 33410959

Group type: EXPERIMENTAL
Intervention: GTV1 before RCT (mean 154.4 ml, 95% CI: 1.5-877)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: GTV2 at 40-50 Gy (mean 106.2 ml, 95% CI: 0.5-589.5)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Absolute decrease from GTV1 to GTV2
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Relative change between GTV1 and GTV2
Number of subjects: 347
Study: 33410970

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 167
Study: 33410985

Group type: EXPERIMENTAL
Intervention: Ketone monoester supplement with a regular carbohydrate-containing diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (regular diet without ketone monoester)
Number of subjects: 0
Study: 33411095

Group type: EXPERIMENTAL
Intervention: Preoperative microcirculatory dysfunction identified by iontophoresis of acetylcholine (ACh)
Number of subjects: 60
Study: 33411231

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2579
Study: 33411364

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (MD score)
Number of subjects: 410

Group type: COMPARATOR
Intervention: High MD scores without statin use
Number of subjects: 410
Study: 33411452

Group type: EXPERIMENTAL
Intervention: Neutral biopsychosocial explanation ('mind and body work together')
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Biomedical explanations ('excitable nerves', 'over-excited state')
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Cognitive framed explanations ('mind is a great storyteller')
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Cognitive bias regarding pain
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Emotional reactions to explanations
Number of subjects: 308
Study: 33411456

Group type: EXPERIMENTAL
Intervention: Same-Day Discharge (SDD) protocol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine care (discharge ≥ postoperative day 1)
Number of subjects: 47
Study: 33411732

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) candidates with motor fluctuations
Number of subjects: 333
Study: 33411755

Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at POD1 in patients with po-AKI
Number of subjects: 93

Group type: COMPARATOR
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at POD1 in patients without po-AKI
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at PO
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) x (IGFBP7) levels at POD1 in KDIGO stage 3 po-AKI patients
Number of subjects: 93

Group type: COMPARATOR
Intervention: Previously proposed cutoff levels (0.3)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Previously proposed cutoff levels (2)
Number of subjects: 93
Study: 33411824

Group type: EXPERIMENTAL
Intervention: ADRe-p intervention (Adverse Drug Reaction Profile for polypharmacy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ADRe-p intervention
Number of subjects: 19
Study: 33411897

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneously at least 1 week before the first cycle of chemotherapy and then every 4 weeks during chemotherapy)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 149
Study: 33411980

Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE) scores of 101-140
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE) scores of >220
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE) scores of ≤100
Number of subjects: 2167
Study: 33412162

Group type: EXPERIMENTAL
Intervention: MYO9A loss of function nonsense heterozygous mutation (p.Arg701)
Number of subjects: 0
Study: 33413235

Group type: EXPERIMENTAL
Intervention: PHQ-9-mFIN
Number of subjects: 64
Study: 33413284

Group type: EXPERIMENTAL
Intervention: Electronic version of the bladder health instrument
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Paper version of the bladder health instrument
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Two-day voiding symptom diary
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: One-day frequency volume diary
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Standardized cough stress test
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Non-invasive urine flowmetry
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Chemical urine analysis
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Post void residual measurement
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Independent judge ratings of bladder health
Number of subjects: 1202
Study: 33413357

Group type: EXPERIMENTAL
Intervention: NIATx200 intervention
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: NIATx200 participation level
Number of subjects: 908
Study: 33413366

Group type: EXPERIMENTAL
Intervention: Diabetic-IR (DIR)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Insulin Sensitive (IS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Likely-IR (LIR)
Number of subjects: 174